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ABSTRACT The procoagulant protein F.VIII:C is
noncovalently bound to von Willebrand factor (vWF) to give
the factor VIII macromolecular complex. New highly purified
preparations of isolated human F.VIII:C, devoid of vWF and
about 500,000-fold purified, were administered to hemophilia
A and von Willebrand disease (vWD) dogs to determine their
hemostatic effectiveness and survival in the circulation. Two
preparations of F.VIII:C were used: peak 1, with active
components ofMr 185,000-280,000, and peak 2, with a single
component ofMr 170,000. In hemophilic dogs, with no plasma
F.VIII:C but normal vWF, both preparations immediately
elevated plasma F.VIII:C to expected levels, promptly stopped
induced and spontaneous hemorrhages, and gave sustained
plasma levels of F.VIII:C. The isolated F.VIII:C immediately
complexed with endogenous vWF in hemophilic plasma and
was eliminated exponentially, with a half-life (t1/2) ofabout 9 hr.
Survival of peak 2 F.VIII:C was longer than that of peak 1
material. In contrast, F.VIII:C complexed to vWF in a
therapeutic concentrate administered to hemophilic dogs was
eliminated biexponentially with first-phase t1/2 of 3.2 hr and
second-phase t1/2 of 9 hr. In vWD dogs with no vWF and
reduced F.VIII:C levels, the isolated F.VIII:C produced
supernormal levels of F.VIII:C without effect on induced
bleeding. It was rapidly eliminated from plasma with a t1/2 of
about 1 hr, as was the complexed F.VIII:C in the concentrate.
These data indicate that isolated F.VIII:C promptly complexes
with vWF and in this form is highly effective in controlling
hemophilic hemorrhages with good survival in plasma. With-
out endogenous vWF with which to complex, the F.VIII:C is
promptly eliminated.
Factor VIII macromolecular complex is composed of two
different noncovalently bound proteins, factor VIII proco-
agulant protein (F.VIII:C) and von Willebrand factor (vWF).
vWF constitutes the larger part of the complex and is
composed of disulfide-linked subunits, each of Mr 200,000.
These subunits form heterogenous multimers ranging from
Mr 400,000 to Mr 12 x 106 (1). vWF is involved in primary
hemostasis and is reduced or defective in individuals with the
autosomal bleeding disorder von Willebrand disease (vWD)
(1). F.VIII:C is involved in secondary hemostasis and plays
a central role in intrinsic blood coagulation. It participates as
a cofactor in the proteolytic-cleavage interaction between
factor IXa and factor X leading to the formation of factor Xa
(2-8). The F.VIII:C protein is lacking or inactive in individ-
uals with classic hemophilia, an X chromosome-linked re-
cessive bleeding disorder. The procoagulant protein can be
dissociated from the F.VIII:C-vWF complex with 0.25 M
calcium chloride or 0.8-1.0M sodium chloride and separated
by size-exclusion chromatography (9-18) or by antigen-
antibody affinity chromatography (19, 20). Recombination of
the two proteins can be accomplished by decreasing the salt
concentration (15, 21). Furthermore, when purified F.VIII:C
is incubated with normal or hemophilic human plasma, it
readily combines with the vWF (22). Because of the low
concentration of F.VIII:C in plasma, it is only recently that
highly purified F.VIII:C free of vWF has been obtained.
Bovine F.VIII:C has been purified approximately 300,000-
fold from plasma (23), and porcine F.VIII:C, 16,000-fold (25).
Purified human F.VIII:C in one preparation had a specific
activity of 2294 F.VIII:C units (u)/mg of protein, represent-
ing a 164,000-fold purification (26), while another preparation
had 4900 u/mg, a 350,000-fold purification (27).
Recently a new procedure for preparation of human
F.VIII:C free of vWF was described (28). The purified
F.VIII:C had a specific activity of about 7000 u/mg, repre-
senting a 500,000-fold purification relative to plasma. The
purified material contained a series of F.VIII:C active com-
ponents with molecular weights ranging from 280,000 down
to 170,000. These components were composed of one light
peptide chain ofMr 80,000 and one heavy chain ofMr varying
from 200,000 to 90,000. In this paper we present data on the
hemostatic effectiveness of infusions of these different
F.VIH:C active components in hemophilic and vWD dogs.
Half-life (tvn) survival studies of the purified F.VIII:C were
also performed in normal, hemophilic, and vWD dogs.
MATERIALS AND METHODS
F.VIII:C Preparation. Purified F.VIII:C free of vWF was
prepared as outlined previously (28). Starting material was
the high-purity factor VIII concentrate, Octonativ (KabiVit-
rum AB, Stockholm, Sweden). The purification procedure
started with an immunoaffinity chromatography step using a
Sepharose CL-2B column containing immobilized antibodies
against vWF. After the adsorption of the F.VIII:C-vWF
complex, the F.VIII:C was dissociated from vWF with 0.5 M
CaCl2. Further purification was obtained by HPLC on Mono
Q gel (Pharmacia, Uppsala, Sweden); F.VIII:C was eluted in
two fractions, having specific activities of 6710 u/mg and
6940 u/mg, respectively. The major and first-eluted fraction
(peak 1) contained eight active components with molecular
weights from 280,000 to 185,000. The F.VIII:C material in the
minor and last-eluted fraction (peak 2) contained only one
component of Mr 170,000. The polypeptide complement of
each fraction was assessed by NaDodSO4/PAGE (28). All
Abbreviations: vWF, von Willebrand factor; vWD, von Willebrand
disease; F.VIII:C, factor VIII procoagulant protein; F.VIII:CAg,
factor VIII coagulant antigen; BT, bleeding time; u, unit(s).
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components in peak 1 consisted of one peptide chain of M,
80,000 and another of Mr varying between 200,000 and
105,000. The component present in peak 2 contained one
peptide chain ofMr 80,000 and another ofMr 90,000. Limited
proteolysis of the peak 1 material with thrombin resulted in
disappearance of the peptide chains ofMr 200,000-105,000 in
parallel with the formation of a Mr 90,000 peptide chain.
Immunological studies and amino acid sequence determina-
tion of the components in peaks 1 and 2 showed that the Mr
80,000 peptide chains were the same in all components and
that the other chains (Mr 90,000-200,000) were all more or
less fragmented products of the Mr 200,000 chain. Thus, the
material contains a series of fragmentation products all of
which are active. This fragmentation did not take place
during the purification, as the same components could be
detected in the starting material by immunoblotting and with
the purification performed in the presence of protease inhib-
itors. The two peptide chains in the F.VIII:C could be
dissociated by exposure to EDTA, indicating one or several
metal-ion bridges. When F.VIII:C was incubated with
hemophilic or normal dog plasma and then was chromat-
ographed on Sepharose CL-6B, the F.VIII:C was eluted in
the void volume, indicating complexing with the plasma
vWF.
F.VIII:C Assays. F.VIII:C assays were performed by a
modified one-stage method (29), using a kaolin-activated
procedure. Human hemophilic substrate was used for the
studies with hemophilic dogs, and canine hemophilic sub-
strate, with vWD dogs. The assay of F.VIII:C using the
synthetic substrate S-2222 (Coatest; KabiVitrum) was per-
formed by the method of Rosen (30). Plasma levels of factor
VIII coagulant antigen (F.VIII:CAg) were determined by a
solid-phase immunoradiometric assay, essentially as de-
scribed by Holmberg et al. (31). Results are expressed as
u/ml; a pooled normal human plasma was used for reference.
vWF Assays. These assays were done with both botrocetin
and ristocetin, using the macroscopic tap-tube procedure
with lyophilized human platelets (32, 33). Canine vWF is
unreactive with ristocetin (33).
Transfusions of F.VIII:C Fractions. For studies on normal
dogs, purified factor VIII:C was labeled with 125I (24) to a
specific activity of 5.3 uCi/,g (1 Ci = 37 GBq) and 3.8
ttCi/tug for peak 1 and peak 2 material, respectively. The
biological activities of 125I-labeled peak 1 and peak 2 material
were 50 and 90% of the initial activities. Two normal beagle
dogs were injected with 4 ,ug of radiolabeled peak 1 material.
Three weeks later the same dogs were injected with 4 ,ug of
labeled peak 2 material. The F.VIII:C-derived 125I radioac-
tivity in citrate-treated plasma samples was precipitated by
trichloroacetic acid and immediately assayed by scintillation
counting.
Both the hemophilia A dogs and the vWD dog were from
the Chapel Hill inbred colonies (34, 35). Table 1 provides
basic information about each animal. The purified F.VIII:C
fractions (3-9 ml) were infused into ajugular vein, as was the
factor VIII concentrate (14-35 ml). Citrate-treated plasma
samples were frozen in 0.2-ml aliquots at -70°C within 20 min
of blood collection. The tj,2 of purified F.VIII:C was deter-
mined by linear-regression analysis after transformation of
F.VIII:C radioactivity (normal dogs) and F.VIII:C activity
(bleeder dogs) values into natural logarithmic values (36). The
slope of the line is -(3 and the half-life is 0.693/,p.
Chromatography on Bio-Gel A-15m was used to determine
whether infused F.VIII:C was complexed with vWF in vivo.
Citrate-treated plasma samples were collected 30 min (bleed-
er animals) or 1 hr (normal animals) after infusion for
chromatography.
Hemostatic Testing. For the hemophilic dogs, a modified
toenail BT (bleeding-time) test (37) was used to test the
hemostatic effectiveness of infused F.VIII:C preparations.
The paw of the front leg was warmed by placing it in isotonic
saline at 37°C and a toenail was trimmed to expose only the
distal matrix. The bleeding nail was placed in isotonic saline
at 37°C and the time until cessation of bleeding was recorded
as the primary BT. The paw was then exposed to air.
Rebleeding of variable duration occurred, with the formation
of a soft red clot over the cut nail matrix. At 2-4 hr, the site
was shaved to remove the clot and as little nail matrix as
possible. The paw was again placed in saline at 37°C. A
discrete stream of extruding blood was visible. Bleeding
continued for 30 min or longer. This is recorded as a
secondary BT of >30 min. For normal dogs, the primary BT
was 2-5 min, the secondary BT <5 min. For testing the
hemostatic effect of infusions of F.VIII:C preparations, a
primary BT test was performed about 4 hr before infusion.
The secondary BT test was performed about 15 min after
infusion. For the vWD dogs, the saline BT test on the ear (38)
was used to determine hemostatic effectiveness of infused
F.VIII:C.
RESULTS
F.VIII:C Administered to Normal Dogs. The experiments in
normal dogs were designed to determine the rate of elimina-
tion of infused F.VIII:C and whether it circulated in plasma
as isolated F.VIII:C or as a complex with vWF. The
F.VIII:C-derived 125I radioactivity declined exponentially
with time (data not shown), and the plasma tl/2 of peak 1 and
2 material was 7.6 and 10.9 hr, respectively. Addition of 40
,ug of unlabeled peak 1 material caused no change in the rate
of elimination. About 90% of the total radioactivity in 1-hr
plasma samples was eluted in the void volume (Bio-Gel A-
15m), suggesting that the infused human F.VIII:C had
complexed in vivo with the canine vWF.
F.VIII:C Administered to Hemophilia A Dogs. The exper-
iments in hemophilic dogs were designed to determine the
survival of infused purified F.VIII:C in the circulation and
the ability of isolated F.VIII:C to control hemophilic hem-
orrhage. For comparison a factor VIII commercial concen-
trate was also used. Table 2 (Exps. 1-3) provides the data on
plasma after infusions of purified F.VIII:C, peaks 1 and 2.
The dose given was calculated to give a plasma F.VIII:C level
of =2.0 u/ml. The response was similar in three hemophilic
Table 1. Hemophilia A and vWD dogs used in F.VIII:C infusion studies
Age, Weight, Plasma F.VIII:C,* u/ml Plasma vWF,t u/ml
Animal Disease months Sex kg One-stage S-2222 F.VIII:CAg Botrocetin Ristocetin
1 Hemophilia 6 F 13.2 <0.01 0.01 0 1.0 <0.01
2 Hemophilia 24 M 16.8 <0.01 0.02 0 1.0 <0.01
3 Hemophilia 12 F 15.6 <0.01 0.02 0 1.0 <0.01
4 Hemophilia 12 F 17.2 <0.01 0.002 0 1.0 <0.01
5 vWD 42 F 7.7 1.0 1.26 0.23 <0.01 <0.01
All animals had a history of hemorrhage.
*Pooled normal human plasma (1.0 u/ml) used as reference standard.
tPreinfusion canine samples (1.0 u/ml) used as reference plasma.
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Table 2. Infusion of human F.VIII:C into hemophilic and vWD dogs
F.VIII:C Infusate Plasma F.VIII:C F.VIII:C tV,
Dose Maximum observed,* u/ml hr
Dog Total Expected, One- Elution One-
Exp. No. Disease Material units u/kg u/ml stage S-2222 F.VIII:CAg fraction stage S-2222
1 1 Hemophilia Peak 1 1350 102 2.05 2.64 2.12 2.10 V0 9.1 6.4
2 2 Hemophilia Peak 2 1820 108 2.17 2.80 2.09 1.67 V0 9.8 9.8
3 3 Hemophilia Peak 1 1500 96 1.92 1.53 ND ND V0 4.2 ND
4 4 Hemophilia Octonativ 1750 102 2.03 2.00 1.03 2.58 VO 9.0t 9.1t
5 5 vWD Peak 1 900 117 2.34* 1.34* 1.52t 1.78t Vi 1.4 0.7
6 5 vWD Octonativ 840 109 2.18t 1.88t 1.640 2.57t V0 1.7 1.1
V0, void volume; Vi, included volume; ND, not done.
*Pooled normal human plasma (1.0 u/ml) used as reference standard.
tSecond-phase half-life (first-phase tl2 was 3.2 hr; ref. 36).




































With either peak 1 or peak 2 infusions, there was an mercial factor VIII concentrate (Table 3, Exp. 4) also
liate rise in the F.VIII:C plasma level. The maximal promptly normalized the secondary BT.
Fusion level of F.VIII:C observed was close to that F.VIII:C Administered to vWD Dog. One homozygous
ted. The F.VIII:C in the postinfusion plasma samples vWD dog was available for the transfusion studies (Table 1).
luted in the void volume from the Bio-Gel A-15m The animal had no detectable plasma vWF and approximate-
i, indicating that the infused F.VIII:C had formed a ly 1.0 u of F.VIII:C/ml, in terms of a human reference plasma
,x with vWF contained in hemophilic plasma. The (equivalent to about 0.3 u of F.VIII:C/ml in relation toa dog
of F.VIII:C (Exp. 2) is illustrated in Fig. 1. There is reference plasma). A transfusion of purified human F.VIII:C
Rood agreement between the results obtained with the was given first, followed by a transfusion of Octonativ
ageclotting procedure and with the synthetic-substrate concentrate 5 days later (Table 2, Exps. 5 and 6). Infusion of
d for measuring F.VIII:C. purified human F.VIII:C caused an increment in plasma
increase in plasma F.VIII:C following infusion of the F.VIII:C of about 1.34-1.78 u/ml, an amount considerably
Drcial factor VIII concentrate into a hemophilic dog is less than the expected value of 2.34 u/ml, suggesting thatinTable2,ctor Exp 4.oThecncrateintrathempalso con .i F.VIII:C not combined with vWF is rapidly lost from thein 2, Exp. etr als ontained .......circulation. Even though F.VIII:C levels were elevated toThe relative amounts of F.VIII:C, vWF/ristocetin, supernormal levels, there was no effect on the long BT (TableWF/botrocetin in the commercial concentrate were 3).
W:2.0. The maximal postinfusion increase in vWF/ris- The comparable experiment with Octonativ in .which the
i was 2.48 u/ml (expected, 2.85 u/ml), and in F.VIII:C was complexed with vWF demonstrated fairly good
botrocetin, 3.85 u/ml (expected, 4.1 u/ml). The agreement between the expected F.VIII:C plasma value and
ision plasma sample contained no vWF/ristocetin and that observed with the one-stage and F.VIII:CAg assays. The
ml vWF/botrocetin. postinfusion plasma vWF/ristocetin values were also close to
ability of infused purified F.VIII:C to control induced those expected. However, there was no correction of the
ihilic bleeding is shown in Table 3, Exps. 1-3. The prolonged bleeding time. In this experiment, there was a
d hemorrhage in the secondary BT test stopped delayed rise in plasma F.VIII:C (e.g., 24 hr. 0.85 u/ml),
fly after F.VIII:C infusions in each experiment. characteristic of the effect of infusions of cryoprecipitate and
ision hemorrhage from secondary BT sites likewise commercial concentrates on plasma F.VIII in v`WD.
d promptly after administration of the purified Survival Studies of F.VIII:C. The very different survival
::C. In Exp. 2 the dog also had a small, continuous, patterns of infused purified F.VIII:C in hemophilia and vWD
Ineous bleed from the mouth. This, too, stopped are shown in Table 2 (last two columns) and in Fig. 2.
iately after infusion. The infusion of the human copm F.VIII:C of peaks 1 and 2 administered to hemophilic dogsdeclined exponentially as it did in normal dogs, with similar
t112 values. The t1,2 was longer with the peak 2 preparation.
Peak 1 F.VIII:C administered to the vWD dog had a very
short tln. These data indicate that the presence of plasma
vWF in the recipient is needed for survival of infused purified
A F.VIII:C.
The survival patterns of F.VIII:C in the concentrate was
likewise very different in hemophilia and vWD. In hemophil-
ia, F.VIII:C declined in a biexponential way. The first-phase
I= Ad- fall-off was 3.2 hr. The second-phase fall-off was about 9 hr,
similar to that observed with peaks 1 and 2 of the purified
F.VIII:C. In vWD, fall-off of F.VIII:C in the concentrate was
very rapid, similar to that observed with purified F.VIII:C,
again indicating the importance of endogenous vWF for
5 10 15 20 25 F.VIII:C survival. The tj,2 for the vWF in the concentrate
Tm hr was also short (tQ12 of 1.3 hr for vWF/ristocetin and 3.2 hr fori e, rvWF/botrocetin).
FIG. 1. Plasma F.VIII:C levels after infusion of purified human
F.VIII:C into a severe hemophilia A dog (Exp. 2). Plasma F.VIII:C
levels were determined by the one-stage bioassay (0o - -o) and by the
chromogenic assay (u-).
DISCUSSION
The F.VIII:C preparations used in these in vivo studies in
hemophilic and vWD dogs were made from a commercial
Proc. Natl. Acad. Sci. USA 82 (1985)
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Table 3. Hemostatic response of hemophilic and vWD dogs to infusions of human F.VIII:C
Infusate Bleeding time, min
Exp. Recipient Type u/kg Primary Secondary Postinfusion
1 Hemophilic Peak 1 102 4.0 >30* 1.0
2 Hemophilic Peak 2 108 6.0 (air) >30* 7.5
3 Hemophilic Peak 1 96 2.0 >30 2.0
4 Hemophilic Octonativ 102 2.0 >30 7.0
5 vWD Peaki 117 >15 ND >15
6 vWD Octonativ 109 >15 ND >15
7 Normal - 3.0 5.0 ND
ND, not done.
*Measured about 1 hr before infusion.
human factor VIII concentrate in which ti
complexed with vWF. The coagulant portioi
VIII complex, F.VIII:C, after dissociation f
was further purified by HPLC with Mon(
F.VIII:C fractions were obtained: peak 1 v
molecular weight components (Mr 280,000-18'
2 with a single active component (Mr 170,000).
peak 2 F.VIII:C fractions or preparations we
rately. Preliminary studies were performed
whether the human F.VIII:C would recombir
both normal and hemophilic canine plasm
studies were performed with administrati
F.VIII:C to normal dogs to determine whethe
protein would combine with the canine vW
whether the human F.VIII:C would circulate i
the finding that cross-species recombination
both occurred, the transfusion experiments
animals were carried out.
Data on the hemophilia A and vWD dogs I
transfusion studies are provided in Table I
hemophilia A dogs, one male and three femal
Although classic human hemophilia occurs ali
ly in males, the canine disease is produced
interbreeding carrier females and hemophi]
vWD subject used in this study was a sever
vWD animal, a product ofthe breeding ofa hoi
and a heterozygous female. The hemophil
lacked F.VIII:C but contained normal amoun
vWD dog plasma lacked vWF but had circu
uncomplexed F.VIII:C of about 1.0 u/ml whe
a human reference standard.
Data from the infusion of the purified F.VIII










FIG. 2. Survival of purified F.VIII:C after inm
philic and vWD dogs. F.VIII:C was measured with
Plasma F.VIII:C values in hemophilia dogs were
infusion of peak 2 (m) or peak 1 (e) material. The F.
the vWD dog were determined after infusion of
preparation.
ie F.VIII:C is F.VIII:C was selected so as to increase the plasma level of
n of the factor this procoagulant to about 2.0 u/ml. After infusion the plasma
rom the vWF, levels of F.VIII:C were immediately elevated to near expect-
D Q gel. Two ed levels. The three separate methods for assay of F.VIII:C,
vith the higher although very different (one a clotting procedure, another a
5,000) and peak chromogenic assay, and the third an immunoassay), gave
The peak 1 and comparable results. The infused human F.VIII:C, both peak
,re tested sepa- 1 and peak 2, complexed with the canine vWF, since both
l to determine were eluted in the void volume. Fig. 1 provides data on the
ie with vWF in fall-off of F.VIII:C in a hemophilic dog infused with the peak
tas. Additional 2 preparation. The infused purified F.VIII:C was highly
ion of human effective in stopping hemophilic hemorrhages (Table 3). Both
r the coagulant peak 1 and peak 2 infusions resulted in a normal secondary
IF in vivo and BT and caused prompt cessation of bleeding from hemor-
n the dog. With rhages then in progress.
n and survival Data obtained from the infusion of purified F.VIII:C into
in the bleeder the vWD animal are presented in Table 2 (Exp. 5). The dose
was comparable to that used for the hemophilic dogs. With
pertinent to the purified F.VIII:C there was an increment ofplasma F.VIII:C
l. Four severe of about 1.5 u/ml, to give a plasma level of about 2.5 u/ml.
les, were used. This postinfusion F.VIII:C level was markedly less than the
most exclusive- expected value. The F.VIII:C was recovered by chromatog-
Lin females by raphy in the included volume eluate, as would be expected
lic males. The since no vWF was present in either the recipient's plasma or
re homozygous the infusate. This infusion of F.VIII:C was without effect on
mozygous male hemostasis (Table 3, Exp. 5). The lack of effect of this high
ic dog plasma level of F.VIII:C is of interest, since there has been specu-
its of vWF. The lation that with two deficiencies in vWD, vWF and F.VIII:C,
elating levels of there might be a beneficial effect on hemostasis with appro-
.n assayed with priate replacement therapy with either factor.
The difference in survival of purified infused F.VIII:C in
I:C preparation hemophilic and vWD dogs was striking (Fig. 2). In
e 2. A dose of hemophilic dogs, F.VIII:C complexed with endogenous plas-
ma vWF survived for hours (tv12 9 hr). In the vWD dog with
an absence of vWF, F.VIII:C was rapidly lost from the
circulation (t012 1 hr). It appears that endogenous vWF is
required for the hemostatic effectiveness and survival of
purified F.VIII:C. Fig. 2 also shows that purified F.VIII:C in
peak 1, with active components of Mr 185,000-280,000, had
a half-life somewhat shorter than did the peak 2 material, with
only a Mr 170,000 component. This difference may indicate
that the smaller the F.VIII:C molecule complexed to the
endogenous vWF, the longer the half-life. Further data are
needed to confirm this interpretation.
The results of infusing human F.VIII:C complexed with
human vWF, Octonativ, into a hemophilic dog (Tables 2 and
3, Exp. 4) are included for comparison to the purified-
20 25 F.VIII:C experiments. The data obtained with the two
preparations were similar in that there was an immediate
fusions in hemo- increase in plasma F.VIII:C and prompt cessation of
S-2222 substrate. hemophilic hemorrhage with both.
t measured after The infusion of the human factor VIII complex into the
'.VIII:C values in vWD dog caused an immediate increase in the plasma
f the peak 1 (A) F.VIII:C. The vWF infused was an integral component ofthe
human factor VIII complex and therefore could be assayed
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with the ristocetin test. Expected levels of vWF/ristocetin,
based on the dose of vWF in the infusate, were reached. As
in human vWD (39), the concentrate did not normalize
hemostasis, presumably because of the limited content of
high molecular weight forms of vWF in this type of prepa-
ration. In addition, there was a secondary or late rise in
F.VIII:C, a characteristic of infusions offactor VIII-complex
preparations in vWD.
In hemophilia the immediate beneficial effects of administer-
ing purified F.VIII:C or the complex were much the same.
However, the postinfusion fall-off of plasma F.VIII:C was
dependent on the form in which it was administered. Purified
F.Vm:C protein that was complexed in vivo with endogenous
vWF followed a simple exponential loss pattern. In the con-
centrate, the human F.VIII:C was already complexed to the
homologous vWF. It followed a biexponential loss pattern.
Here the role of the endogenous vWF is less clear. Perhaps the
more rapid first-phase fall-off (tQ = 3.2 hr) is due to the rapid
loss of the infused vWF in the complex, carrying part of the
F.VIII:C with it. The second phase (tu2 = 9 hr) may represent
the fall-off of F.VIII:C that had been transferred to the endog-
enous vWF carrier which is in a steady-state condition. This is
suggested by the second-phase half-life, which is similar to that
of the purified F.VIII:C complexed to the endogenous vWF in
Exp. 2 (tV2 = 9 hr) and the loss ofristocetin-sensitive vWF. The
net effect of these two patterns of survivals is that higher levels
of plasma F.VIII:C are sustained in hemophilic dogs with
infusion of the purified form of F.VIII:C than with the
F.VIII-vWF complex, dosage being the same. These data
suggest that for maximum biologic effectiveness in hemophilic
therapy it would be advantageous to use purified F.VIII:C, such
as the preparations tested here or recombinant F.VIII:C. The
latter also complexes with vWF (40). In the vWD dog, the
F.VIII:C in the concentrate resulted in higher plasma levels of
F.VIII:C which remained in the postinfusion plasma somewhat
longer than did purified F.VII:C. These findings suggest that
preinfusion complexing of the coagulant protein to vWF has a
very limited effect on F.VIII:C survival.
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